Veracyte (VCYT) Q4 2024 earnings summary

Executive summary

• Achieved record 2024 revenue of $446M, up 23% YoY, with Q4 revenue of $119M, driven by Decipher and Afirma platforms.

• Testing revenue comprised 95% of business, growing 28% YoY, led by Decipher (volume up 36% YoY, 45% in Q4) and Afirma (volume up 12% YoY).

• Returned to profitability with 2024 GAAP net income of $24M, compared to a net loss in 2023.

• Adjusted EBITDA margin improved to 20.6% in 2024; ended year with $289.4M in cash and equivalents.

• Strategic focus on expanding Decipher into metastatic prostate cancer and advancing MRD platform.

Financial highlights

• Q4 2024 revenue: $119M (+21% YoY); Q4 testing revenue: $112M (+24% YoY).

• Full-year adjusted EBITDA: $91.9M (20.6% margin); Q4 adjusted EBITDA: $26.1M (22% margin).

• Full-year non-GAAP gross margin: 70.0%; testing ASP ~$2,875.

• Ended 2024 with $289.4M in cash and equivalents; generated $75.1M in operating cash flow.

• GAAP net income for Q4: $5.1M; Q4 GAAP effective tax rate: -48.5% due to $356M worthless stock deduction.

Outlook and guidance

• 2025 testing revenue guidance: $470M–$480M (12%–15% YoY growth); adjusted for Envisia exit, growth would be 14%–16%.

• Adjusted EBITDA margin expected to improve by ~100 bps in 2025, targeting ~21.6%.

• Metastatic Decipher launch expected to impact volumes in H2 2025 and beyond; initial contribution in 2025 will be small.

• One-time costs in 2025 related to France business up to $15M; potential $13M annualized profit improvement post-2025.

• No total company revenue guidance for 2025 due to uncertainty regarding Marseille, France operations.